Expression of two copies of mutant HRAS results in the development of noninvasive bladder cancer at 6 months, and we saw identical urothelial regression in these animals following Upk2-Cre mediated Foxa1 KO (see supplemental data). This evidence concerns the gene FOXA1 and urinary bladder carcinoma.